Idaho Independent Bank Announces 2015 First Quarter Results

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Idaho Independent Bank Announces 2015 First Quarter Results

COEUR D'ALENE, Idaho, April 10, 2015 (GLOBE NEWSWIRE) -- Jack W. Gustavel, Chairman and Chief Executive Officer of Idaho Independent Bank ("IIB" or the "Bank") (OTCBB: IIBK ), announced IIB's consolidated unaudited financial results for the quarter ended March 31, 2015.

"I am pleased to report improved core earnings and excellent loan and deposit growth during the past twelve months," Mr. Gustavel said. IIB's net income for the quarter was $358,000, or $0.04 per diluted share, compared to net income of $458,000, or $0.06 per diluted share, for the same period a year ago. It should be noted that income for the first quarter of 2014 included $858,000 in non-recurring interest received during that quarter. Also, income tax expense for the first quarter of each year was offset by a reduction in the Bank's valuation allowance against net deferred tax assets.  

At March 31, 2015, the Bank's total assets were $533.5 million, an increase of $60.8 million, or 12.9%, compared to March 31, 2014. Deposits and repurchase agreements increased $52.6 million, or 13.2%, to $452.3 million; while total loans, including loans held-for-sale, increased $40.7 million, or 17.6%, to $272.5 million over the same timeframe. The Bank had net loan loss recoveries of $47,000 during the current quarter, and at March 31, 2015, the allowance for loan and lease losses totaled $6.5 million, or 2.5% of total loans, excluding loans held-for-sale. Nonperforming assets were less than 0.4% of total assets at March 31, 2015.

As of March 31, 2015, the Bank's Stockholders' Equity to Average Total Assets Ratio was 11.1% and IIB estimates its capital ratios exceeded the regulatory thresholds required to be considered "Well-Capitalized" by a significant margin.  

IIB will file its Consolidated Report of Condition and Income for the quarter ended March 31, 2015, ("Call Report") with the Federal Deposit Insurance Corporation by April 30, 2015, and it will be available on the Federal Financial Institutions Examinations Council website at http://cdr.ffiec.gov/Public/ .

About IIB

IIB was established in 1993 as an Idaho state-chartered, commercial bank and currently operates three branches in Boise, as well as branches in Meridian, Coeur d'Alene, Nampa, Mountain Home, Hayden, Caldwell, Star, and Sun Valley/Ketchum, Idaho. IIB has approximately 200 employees throughout the State of Idaho. To learn more about IIB, visit us online at www.theidahobank.com .

Statements contained herein concerning future performance, developments or events, expectations for earnings, growth and market forecasts, and similar statements that are not historical facts are intended to be "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995, and as such, are subject to a number of risks and uncertainties that might cause actual results to differ materially from expectations or our stated objectives. Factors that could cause actual results to differ materially, include, but are not limited to, declines in regional and general economic conditions; changes in interest rates, deposit flows, demand for loans, real estate values, competition, or loan delinquency rates; changes in accounting principles, practices, policies, or guidelines; changes in legislation or regulations; changes in the regulatory environment; changes in monetary policy of the Federal Reserve Bank; changes in fiscal policy of the Federal government and the State of Idaho; changes in other economic, competitive, governmental, regulatory and technological factors affecting operations, pricing, products, and services; material unforeseen changes in the liquidity, results of operations, or financial condition of the Bank's customers. Accordingly, these factors should be considered in evaluating forward-looking statements, and undue reliance should not be placed on such statements. The Bank undertakes no responsibility to update or revise any forward-looking statements.

Idaho Independent Bank
Financial Highlights (unaudited)
(dollars in thousands, except share data)
     
  Three Months Ended
CONDENSED STATEMENT OF OPERATIONS March 31,
  2015 2014
Net interest income  $ 3,772  $ 4,185
Provision for loan losses  --  --
Net interest income after provision for loan losses  3,772  4,185
Noninterest income  1,404  1,287
Noninterest expense  4,818  5,014
Net income before taxes  358  458
Income tax expense (benefit)  --  --
Net income  $ 358  $ 458
     
Earnings per share:    
 Basic  $ 0.04  $ 0.06
 Diluted  $ 0.04  $ 0.06
     
SELECTED BALANCE SHEET ACCOUNTS March 31, March 31,
  2015 2014
Loans held for sale  $ 7,885  $ 1,690
Loans receivable  264,592  230,146
Gross loans  272,477  231,836
Allowance for loan losses  6,492  6,156
Total assets  533,471  472,694
Deposits  430,936  389,248
Customer repurchase agreements  21,339  10,450
Total deposits and repurchase agreements  452,275  399,698
Stockholders' equity  60,022  54,822
     
PER SHARE DATA    
Common shares outstanding  8,205,838  8,181,949
Book value per share  $ 7.31  $ 6.70
     
  Three Months Ended
PERFORMANCE RATIOS (annualized) March 31,
  2015 2014
Return on average assets 0.27% 0.40%
Return on average equity 2.43% 3.39%
Efficiency ratio 93.08% 91.63%
Net interest margin 3.06% 4.04%

Jack W. Gustavel IDAHO INDEPENDENT BANK 1260 W. Riverstone Drive Coeur d'Alene, Idaho 83814 (208) 292-1902

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 627

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 364

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 153

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
Cultural Tech Fusion: The Asia-Pacific Way Forward

Updated Category News Views 64

A High-Tech Twist on Traditional Culture You ever walk into a room and see a robot perform kung fu? I'll admit, it caught me off guard at first. But that's exactly what happened at the "Enduring Heritage, Harmonious Asia-Pacific" special exhibition in Shenzhen. With all the usual high-ranking execs and cultural bigwigs there, nobody expected a showcase where Wing Chun...

Continue Reading
Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 257

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 35

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
ASMAX Unleashes Next-Level Motorcycle Comms at EICMA

Updated Category News Views 50

Transforming the Motorcycle Communication Landscape Motorcycling ain't just about the roaring engines and the rubber on the road. In the world of helmets and handlebars, some bright minds are weaving tech magic at the EICMA 2026 in Milan. ASMAX has rolled out its shiny new RoamX intercom gadget, leaving folks buzzing at Hall 6. What RoamX Brings to the Table This ain't...

Continue Reading
Stavian Group Eyes AI-Driven Southeast Asia Growth

Updated Category News Views 85

AI and Infrastructure: A New Chapter for Southeast Asia What does Southeast Asia's future look like with AI steering the ship? Well, there's a fresh breeze of change blowing, and right at the heart of it stands Stavian Group. At the recently held inaugural Fortune SEA500 Summit in Ho Chi Minh City, this conglomerate threw its hat into the ring, painting a vision of growth...

Continue Reading
Wuliangye Aims for Global Branding Boost at Panda Event

Updated Category News Views 52

Wuliangye Takes Center Stage at Global Event Everyone's chasing that global branding magic, but here's Wuliangye strutting its stuff at the Global Panda Partners Conference. Held in Sichuan Province from November 2 to 4, this is not just another show; it's a bold move from the Chinese baijiu maker to push the 'harmony and coexistence' mantra on the world stage. Not just...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 110

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading

Top 5 Most Recently Viewed Articles

DESRI Completes Major Financing for Texas Solar Projects

Updated Category News Views 324

DESRI Completes Major Financing for Texas Solar Projects Today, DESRI proudly announced that it has closed a significant preferred equity financing of $129 million aimed at a 250-megawatt (MWac) solar development portfolio. This portfolio consists of two innovative solar projects located in West Texas, an area ripe for renewable energy enhancement. Meeting Industrial...

Continue Reading
Colossal Foundation Invests $500,000 in Condor Restoration Efforts

Updated Category News Views 76

Colossal Foundation Invests in Wildlife Recovery The Colossal Foundation has made a significant commitment of $500,000 towards restoring the California condor to its ancestral skies. This incredible movement represents a decade-long partnership with the Nez Perce Tribe, focusing on the recovery and reintroduction of North America’s largest land bird. For more than a...

Continue Reading
Revolutionary Self-Healing Film: The Future of Waterproofing

Updated Category News Views 108

Revolutionary Waterproofing Solutions by Charter Next Generation Charter Next Generation (CNG) recently unveiled its groundbreaking Nail Sealable film technology, designed to transform waterproofing in the construction industry. This pioneering self-healing film stands out with its exceptional moisture resistance and remarkable durability, making it a game changer for...

Continue Reading
Sonnet BioTherapeutics Provides Positive Safety Insights on SON-1010

Updated Category News Views 273

Exciting Safety Data from Sonnet BioTherapeutics’ SON-1010 Trial Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has unveiled impressive topline safety data following a successful dose escalation of SON-1010 in the Phase 1 SB101 clinical trial. The study focused on the administration of SON-1010 to patients suffering from advanced solid tumors, marking a significant...

Continue Reading
Key Legal Information for Symbotic Inc. Shareholders

Updated Category News Views 73

Important Information for Symbotic Inc. Investors Recent developments surrounding Symbotic Inc. have captured the attention of investors globally. Investors who are shareholders of Symbotic Inc. (NASDAQ: SYM) may need to be aware of significant deadlines regarding a recent securities class action lawsuit. Overview of the Lawsuit Investors are reminded that they may have...

Continue Reading